FDA issues new Plavix warning
The agency released a statement Friday regarding the inability of some patients to process the drug.
Washington (WiredPRNews.com) – The Food and Drug Administration has issued a black box warning for the drug Plavix. As reported by the Associated Press (AP), the FDA released a statement Friday saying some individuals may have an inability to metabolize the blood thinner, which is prescribed for the prevention of blood clots, due to a genetic variation, which may increase their risks of heart attack and stroke.
The FDA is quoted by the AP as stating in a statement released online, “Patients should not stop taking Plavix unless told to do so by their health care professional… They should talk with their health care professional if they have any concerns about Plavix, or to find out if they should be tested for being a poor metabolizer.”
WiredPRNews.com – The latest in Medical News
Photo Credit: Wikipedia User Trounce
Tags: black box warning, blood thinner, FDA, heart attack, metabolize, metabolizer, Plavix, strokeOnline Medical News News Press Release Distribution - WiredPRNews.com
- Soprano Laser Hair Removal Now More Effective then IPL
- High Dose Rate Electronic Radiation Skin Cancer Treatment Now Available in US
- Sandusky Accusers Get Foundation’s Help
- Houston Pilates instructor now equipped to help post-operative breast cancer survivors
- Compounding Pharmacy Offers Solution for Mibolerone (Cheque Drops) Shortage
- Physical Therapy Documentation Software Maker Shares iOS5 Tips
- PD Patient Advises, “Key to staying active — stay active!”
- Missing Teeth No Longer Stand in the Way of a Beautiful Smile
- Presidential Candidate Brain Freeze Common in Peri-Menopausal Women
- Cate School Launches Long-Term Study to Monitor Adolescent and Young Adult Hearts
